In addition, LCN2 has been suggested as a new biomarker for the current status of depression, as its plasma levels correlate with the depression severity in elderly patients with major depressive disorder and are unaffected by the use of antidepressants or onset of depression, unlike other inflammatory markers (e.g., C-reactive protein and interferon alpha) [40]. Here, LCN2 is linked to depressive symptom measurement.